Literature DB >> 7076296

Early clearance of pneumococci from the lungs of decomplemented rats.

S R Rehm, J D Coonrod.   

Abstract

Pneumococcal types which exhibited varying degrees of interaction with the complement system in vitro wee aerosolized into normal and decomplemented rats, and the rate of killing of pneumococci was monitored by serial cultures of whole lung homogenates. The clearance of pneumococci from the alveoli did not correlate with the ability of the pneumococci to be opsonized by complement in vitro. Similarly, rats depleted of complement in the serum and the bronchoalveolar lavage fluid maintained their ability to rapidly inactivate aerosolized pneumococci. These results indicate that the early phase of pneumococcal killing in the alveoli does not require complement and suggest that in the nonimmune host, phagocytosis by alveolar macrophages can be achieved without complement-dependent opsonization or, alternatively, that extracellular factors rapidly inactivate inhaled pneumococci.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076296      PMCID: PMC351179          DOI: 10.1128/iai.36.1.24-29.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Determinants of lung bacterial clearance in mice after acute hypoxia.

Authors:  G D Harris; W G Johanson; A K Pierce
Journal:  Am Rev Respir Dis       Date:  1977-10

2.  Factors influencing the immune enhancement of intrapulmonary bactericidal mechanisms.

Authors:  G J Jakab
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Determinants of lung bacterial clearance in normal mice.

Authors:  S J Jay; W G Johanson; A K Pierce; J S Reisch
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

4.  Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.

Authors:  G S Giebink; J Verhoef; P K Peterson; P G Quie
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

5.  Leukocytic response to inhaled bacteria.

Authors:  A K Pierce; R C Reynolds; G D Harris
Journal:  Am Rev Respir Dis       Date:  1977-10

6.  Pulmonary cell reactions after exposure to cotton dust extract.

Authors:  R Rylander; A Nordstrand
Journal:  Br J Ind Med       Date:  1974-07

7.  Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material.

Authors:  F M LaForce; W J Kelly; G L Huber
Journal:  Am Rev Respir Dis       Date:  1973-10

8.  Assay of complement components C1, C4, C2, C3 and C9 in whole rat serum.

Authors:  J R Caldwell; S Ruddy; K F Austen
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

9.  Bacterial growth in vivo. An important determinant of the pulmonary clearance of Diplococcus pneumoniae in rats.

Authors:  W G Johanson; J J Stephen; A K Pierce
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material.

Authors:  J A Juers; R M Rogers; J B McCurdy; W W Cook
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

View more
  4 in total

1.  Detection and partial characterization of antibacterial factor(s) in alveolar lining material of rats.

Authors:  J D Coonrod; K Yoneda
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

2.  Comparative role of complement in pneumococcal and staphylococcal pneumonia.

Authors:  J D Coonrod; K Yoneda
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

3.  Characterization of the extracellular bactericidal factors of rat alveolar lining material.

Authors:  J D Coonrod; R L Lester; L C Hsu
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

4.  Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice.

Authors:  Zhe Zhang; Thomas B Clarke; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.